Nipocalimab hit its SLE endpoint in 2026; J&J's Q2 release restates it without new data
The Phase 2 JASMINE trial met its SRI-4 primary endpoint earlier this year; J&J's July 15 earnings release recaps the finding but adds no new numbers as Phase 3 GARDENIA continues enrolling.
Executive Summary
- Nipocalimab's Phase 2 SLE trial met its primary endpoint earlier in 2026, and Johnson & Johnson's July earnings release simply recaps that finding rather than disclosing anything new.
- The result gives J&J a positive proof-of-concept for FcRn blockade in systemic lupus erythematosus, a mechanism with essentially no other lupus-specific competitor at this stage.
- The result is already carrying forward into a Phase 3 registrational trial, so the open question is no longer whether the mechanism works in SLE but whether the effect holds at the larger, longer-duration bar Phase 3 sets.
- The earnings-release framing lacks the numeric detail the earlier disclosures provided, which is a reminder that the primary evidentiary record sits in the prior readouts, not in this quarter's language.
The result, restated
Johnson & Johnson's second-quarter earnings release on July 15, 2026 stated that nipocalimab produced a reduction in SLE disease activity, without giving response rates, a timepoint, or a p-value. That framing matches, but adds nothing to, disclosures the company had already made this year: in January and again in March 2026, J&J reported that the Phase 2b JASMINE study (NCT04882878) met its primary endpoint, the percentage of participants achieving an SLE Responder Index (SRI)-4 composite response at Week 24. By June 2026, the company had put a number on it: nipocalimab at 15 mg/kg produced a 53.5% SRI-4 response at Week 24 versus 46.7% for placebo, with the response sustained through Week 52 and a stronger effect in autoantibody-positive patients. Johnson+1Johnson & Johnson reports Q2 2026 results, raises 2026 outlookJul 15, 2026A Study of Nipocalimab in Adult Participants With Active Systemic Lupus ErythematosusNCT04882878
The trial behind the number
JASMINE enrolled 228 adults with active SLE across the United States, Japan, Poland, Ukraine, Argentina, Colombia, Spain, Taiwan, Bulgaria, Hungary, South Africa and Germany, and completed with that enrollment matching its target. The trial's primary completion date moved three times during conduct, from July 2023 to December 2024 to May 2024 and finally to April 30, 2024, a net pull-in from the original registered date. Enrollment rose modestly from an anticipated 225 to an actual 228 as the study closed. The study reached Completed status in January 2025, roughly a year after its final primary completion date, and the topline result did not surface publicly until January 2026. NCT04882878A Study of Nipocalimab in Adult Participants With Active Systemic Lupus ErythematosusNCT04882878
What it feeds
The JASMINE result is not a standalone data point. It underwrites the ongoing Phase 3 GARDENIA study (NCT07438496), which is recruiting toward its own SRI-4 composite response endpoint at Week 52 and carries a December 2028 completion target. Nipocalimab also holds FDA Fast Track designation in SLE, a designation tied to this development program though it does not itself signal a completed regulatory review. Together, the Phase 2 result and the Fast Track designation position nipocalimab's SLE program to run on JASMINE's evidence base until GARDENIA reads out. JohnsonJohnson & Johnson reports Q2 2026 results, raises 2026 outlookJul 15, 2026
The competitive field
FcRn blockade has a broader footprint outside SLE: argenx's efgartigimod and UCB Pharma's rozanolixizumab are direct FcRn-targeting comparators approved and in ongoing trials for myasthenia gravis, and Immunovant's IMVT-1402 is testing the same target in rheumatoid arthritis. Within systemic lupus erythematosus specifically, nipocalimab has no other FcRn-targeting trial competing for the indication; the closest same-modality precedents in SLE, AstraZeneca's anifrolumab and Novartis's ianalumab, work through different targets (IFNAR1 and BAFF receptor, respectively). That structure makes JASMINE's result the only FcRn evidence base in SLE to date, and it is the data GARDENIA now has to reproduce at Phase 3 scale.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.